ClinicalTrials.Veeva

Menu
N

Nouvelle Clinical Research | Cutler Bay, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

AD109
Atomoxetine
Tc 99m
Allopurinol
AP1189
Aroxybutynin
Lorundrostat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis

The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral A...

Enrolling
Rheumatoid Arthritis (RA)
Drug: AP1189, 70 mg
Drug: AP1189 matching placebo

The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participan...

Active, not recruiting
Hypertension
Obstructive Sleep Apnea
Drug: Placebo
Drug: Lorundrostat

The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure...

Enrolling
Diastolic Heart Failure
Heart Failure With Preserved Ejection Fraction
Device: OPTIMIZERâ„¢ Smart Mini System
Device: Cardiac Contractility Modulation Therapy via OPTIMIZERâ„¢ Smart Mini System

The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep...

Invitation-only
OSA
Drug: Aroxybutynin and Atomoxetine

Trial sponsors

Apnimed logo
I
LG Chem logo
M
N
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems